A detailed history of Cubist Systematic Strategies, LLC transactions in Zai Lab LTD stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 96,350 shares of ZLAB stock, worth $2.44 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
96,350
Holding current value
$2.44 Million
% of portfolio
0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.25 - $24.14 $1.57 Million - $2.33 Million
96,350 New
96,350 $2.33 Million
Q4 2022

Feb 14, 2023

BUY
$22.28 - $38.71 $1.1 Million - $1.91 Million
49,237 New
49,237 $1.51 Million
Q2 2022

Aug 15, 2022

BUY
$23.14 - $49.68 $633,966 - $1.36 Million
27,397 Added 61.07%
72,258 $2.51 Million
Q1 2022

May 16, 2022

BUY
$27.77 - $64.4 $1.22 Million - $2.83 Million
43,977 Added 4974.77%
44,861 $1.97 Million
Q4 2021

Feb 14, 2022

SELL
$54.9 - $105.21 $1.23 Million - $2.36 Million
-22,387 Reduced 96.2%
884 $56,000
Q3 2021

Nov 15, 2021

BUY
$105.0 - $178.37 $2.44 Million - $4.15 Million
23,271 New
23,271 $2.45 Million
Q2 2021

Aug 16, 2021

SELL
$125.11 - $180.0 $1.02 Million - $1.47 Million
-8,148 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$126.27 - $191.71 $1.03 Million - $1.56 Million
8,148 New
8,148 $1.09 Million
Q3 2020

Nov 16, 2020

SELL
$73.3 - $89.48 $675,826 - $825,005
-9,220 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$48.82 - $82.53 $450,120 - $760,926
9,220 New
9,220 $757,000
Q1 2020

May 15, 2020

SELL
$39.1 - $62.9 $687,065 - $1.11 Million
-17,572 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$29.79 - $43.06 $519,984 - $751,612
17,455 Added 14918.8%
17,572 $731,000
Q3 2019

Nov 14, 2019

BUY
$30.47 - $37.65 $3,564 - $4,405
117 New
117 $4,000

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.48B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.